Please login to the form below

Not currently logged in

bluebird bio temporarily suspends trials of sickle cell gene therapy LentiGlobin

Company will also suspend marketing of beta-thalassemia gene therapy Zynteglo

bluebird bio has announced that it will temporarily place phase 1/2 and phase 3 trials of its sickle cell disease (SCD) gene therapy LentiGlobin on hold after a report of a suspected unexpected serious adverse reaction (SUSAR).  

The reported SUSAR is a case of acute myeloid leukaemia. The patient, included in group A of the phase 1/2 HGB-206 study, was treated more than five years ago with bluebird gene therapy.

In a statement, bluebird said that it is investigating the cause of this patient’s AML diagnosis, to determine if there is a relationship between the use of the BB305 lentiviral vector in the manufacture of LentiGlobin for SCD.

Another SUSAR of myelodysplastic syndrome (MDS) in a patient from group C of HGB-206 was also reported last week, which bluebird also said it is currently investigating.

Although no cases of haematologic malignancy have been reported in any patient that has been treated with the gene therapy in beta-thalassemia, where it is marketed as Zynteglo, the company has temporarily suspended marketing of the treatment while it investigates the AML case.

This is because Zynteglo is manufactured using the same BB305 lentiviral vector used in LentiGlobin SCD.

“The safety of every patient who has participated in our studies or is treated with our gene therapies is the utmost priority for us,” said Nick Leschly, chief executive officer of bluebird.

“We are committed to fully assessing these cases in partnership with the healthcare providers supporting our clinical studies and appropriate regulatory agencies. Our thoughts are with these patients and their families during this time,” he added.

bluebird added that it will continue to work with regulatory agencies to complete its investigation, adding that the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have been advised of both cases.

Article by
Lucy Parsons

16th February 2021

From: Regulatory



COVID-19 Updates and Daily News

Featured jobs


Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....